Xbrane Biopharma: CRL follow-up note - Redeye

Redeye publishes a follow-up note subsequent to yesterday's conference call concerning sunday's CRL from the FDA. We make revisions to our assumptions for Ximluci in the US market, resulting in a lower base case. We also discuss the financing outlook.

Länk till analysen i sin helhet: https://www.redeye.se/research/996618/xbrane-biopharma-crl-follow-up-note?utm_source=finwire&utm_medium=RSS